Literature DB >> 28958674

National Practice Patterns and Outcomes for T4b Urothelial Cancer of the Bladder.

Waqar Haque1, Vivek Verma2, E Brian Butler3, Bin S Teh4.   

Abstract

PURPOSE: Management of cT4b bladder cancer is poorly defined; national guidelines recommend chemotherapy (CT) alone or chemoradiation (CRT). Using a large, contemporary dataset, we evaluated national practice patterns as well as associated outcomes, especially with respect to radical cystectomy (RC) and CRT versus CT alone.
METHODS: The National Cancer Data Base was queried (2004-2013) for patients diagnosed with cT4bN0-3M0 bladder cancer. Patients were divided into 5 treatment groups: CT alone, CRT, RC (with/without CT/radiotherapy [RT]), other treatment (subtherapeutic RT with/without CT), or no treatment. Statistics included multivariable logistic regression to determine factors predictive of observation, Kaplan-Meier analysis to evaluate overall survival (OS), and Cox proportional hazards modeling to determine variables associated with OS.
RESULTS: Of 896 total patients, 185 (20.6%) underwent CT alone, 80 (8.9%) CRT, 161 (18.9%) RC, 221 (24.7%) other treatments, and 249 (27.8%) observation. Differences in treatment paradigms were appreciated based on age, gender, nodal status, insurance, and facility-related parameters. Observation yielded a median OS of 3.7 months, lower than CT alone (P < .001). As compared with the latter, CRT was associated with higher OS (10.5 vs. 12.1 months, P = .004). RC-based treatment displayed the numerically highest OS (14.2 months) and was statistically similar to CRT (P = .676). Treatment with any modality independently predicted for superior OS over observation.
CONCLUSIONS: In the largest study of its kind, a surprisingly high proportion of patients underwent observation. CRT is associated with higher survival over CT alone, and carefully selected patients undergoing RC may experience prolonged survival.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Chemoradiation; Chemotherapy; Cystectomy; Radiation therapy

Year:  2017        PMID: 28958674     DOI: 10.1016/j.clgc.2017.08.013

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  7 in total

1.  Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Neurooncol       Date:  2017-10-31       Impact factor: 4.130

2.  National Cancer Database report of nonmetastatic esophageal small cell carcinoma.

Authors:  Vivek Verma; Richard L Sleightholm; Penny Fang; Jeffrey M Ryckman; Chi Lin
Journal:  Cancer Med       Date:  2018-11-06       Impact factor: 4.452

3.  Utilization of intensity modulated radiation therapy for anal cancer in the United States.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2018-06

4.  Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base.

Authors:  Vivek Verma; Adams Kusi Appiah; Tim Lautenschlaeger; Sebastian Adeberg; Charles B Simone; Chi Lin
Journal:  J Gastrointest Oncol       Date:  2018-06

5.  Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry.

Authors:  Mohd Nasrullah Nik Ab Kadir; Suhaily Mohd Hairon; Najib Majdi Yaacob; Azizah Ab Manan; Nabihah Ali
Journal:  Int J Environ Res Public Health       Date:  2021-05-14       Impact factor: 3.390

6.  Practice patterns and outcomes of chemoradiotherapy versus radiotherapy alone for older patients with nasopharyngeal cancer.

Authors:  Vivek Verma; Swati M Surkar; Amy C Moreno; Chi Lin; Charles B Simone
Journal:  Cancer Med       Date:  2018-03-30       Impact factor: 4.452

7.  Prognostic Factors for Bladder Cancer Patients in Malaysia: A Population-Based Study.

Authors:  Mohd Nasrullah Nik Ab Kadir; Suhaily Mohd Hairon; Najib Majdi Yaacob; Azizah Ab Manan; Nabihah Ali
Journal:  Int J Environ Res Public Health       Date:  2022-03-04       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.